---
layout: post
title: "奥赛康子公司盐酸左布比卡因注射液通过仿制药一致性评价"
date: 2022-01-25 19:43:39 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002755" data-code="002755|0|2" data-code2="002755|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002755&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002755_0" data-code="K 002755|0|2" data-code2="K 002755|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>奥赛康公告，公司全资子公司江苏奥赛康药业有限公司于近日收到国家药品监督管理局核准签发的盐酸左布比卡因注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201252261330988>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)